Argenx shares plunge 16% after Sjögren’s drug trial halted

🌐 Investing.com (BE) —
Argenx shares plunge 16% after Sjögren’s drug trial halted

AI Summary

Argenx shares dropped 16% after the company halted a clinical trial of a drug targeting Sjögren’s disease. The trial decision is a healthcare setback and drove a sharp market reaction.

Markets Health argenx Sjögren’s disease clinical trial trial halted shares plunge drug development

Read original source →